Gilead Sciences, Inc. has made two appointments to the company's senior leadership team. Kevin Young has been appointed chief operating officer, and Martin Silverstein, MD, has been appointed executive vice president, strategy. Both Mr. Young and Dr. Silverstein will report to John F. Milligan, Gilead’s president and chief executive officer. The company also announced that Paul R. Carter, executive vice president, commercial operations, has decided to depart Gilead and pursue other opportunities.

As chief operating officer, Mr. Young will assume responsibility for Gilead's worldwide commercial organization, including facilities and operations. From 2004 through 2014, Mr. Young served as Gilead's executive vice president of commercial operations. Since 2014, he has held the role of senior advisor to the company. Prior to Gilead, he spent more than 20 years in the biopharmaceutical industry, first with ICI Pharmaceuticals and subsequently with Amgen.

Dr. Silverstein will oversee Gilead's corporate development, commercial planning and alliance management functions. He previously held the role of executive vice president and chief strategy officer at Anthem from April 2014 through December 2015. Prior to Anthem, Dr. Silverstein spent 28 years in roles of increasing responsibility at The Boston Consulting Group, including serving as global leader of its healthcare practice, senior partner and managing director.

Source: Gilead Sciences